ClinicalTrials.gg
CompletedNCT00127478Updated Nov 29, 2007

A Long Term Safety Study With Atrasentan

A Phase 2/3 interventional study of Atrasentan in Prostate Cancer and Adenocarcinoma, sponsored by Abbott. Completed at 15 sites in 5 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2007-11-29.

Sponsored by Abbott · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
166
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Prostatic Neoplasms by Abbott — none open to participants now, none under way, none of them phase 3. Prostatic Neoplasms · Abbott.

Started
2001
with 2 others
Phase 2/3
Only one
of the 12
Registered
6th of 12
by date

Among the 12 studies in Prostatic Neoplasms by Abbott, this one is one of 3 that started in 2001, is the only one in phase 2/3, and was the 6th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

None of the 12 studies in Prostatic Neoplasms by Abbott is open now. The open studies under Prostatic Neoplasms, anywhere →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Prostatic Neoplasms by Abbott as a file.
02

Study summary

The primary purpose of the study is to evaluate long-term safety and tolerability of atrasentan 10 mg in men with hormone refractory prostate cancer.

03

Conditions studied

  • Prostate Cancer
  • Adenocarcinoma

Keywords

  • Hormone Refractory Prostate Cancer
  • Adenocarcinoma of the Prostate
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Greater than or equal to 18 years, inclusive;
  • Subject is currently active in an atrasentan clinical study OR has or cytologically documented diagnosis of prostate adenocarcinoma and is considered hormone ;
  • Performance Score greater than or equal to 60;
  • Adequate hematologic function and liver function tests;
  • No (NYHA) class greater than or equal to 2.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
166 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Adverse events

    Time frame: Every 12 weeks

  2. Serious adverse events

  3. Oncology-related events (OREs)

  4. Deaths

  5. Study drug exposure

  6. Change from baseline in Karnofsky performance status

  7. Vital signs

  8. Stratification by treatment group from prior study

Secondary outcomes

  1. Safety and laboratory parameters

    Time frame: Every 12 weeks

07

Study locations

15 sites
  • Prostate Oncology Specialists
    Marina del Rey, California 32589, United States
  • Western Clinical Research, Inc.
    Torrance, California 90505, United States
  • South Florida Medical Research
    Aventura, Florida 33180, United States
  • Beth Isreal Medical Center, Phillips Ambulatory Care Ceneter
    New York, New York 10003, United States
  • ViaHealth Rochester General Hospital Center for Urology
    Rochester, New York 14609, United States
  • Oregon Urology Specialist, Division of Clinical Research
    Springfield, Oregon 97477, United States
  • University of Pittsburgh Department of Urology
    Pittsburgh, Pennsylvania 15232, United States
  • Cross Cancer Institute
    Edmonton, Alberta T6G 1Z2, Canada
  • CroMedia Prime/Prime Trials Vancouver Hospital
    Vancouver, British Columbia V5Z 1M9, Canada
  • Ken Janz MD
    Burlington, Ontario 3V2CAN, Canada
  • McMaster Institute of Urology
    Hamilton, Ontario L8N 4A6, Canada
  • McGill University Health Center Royal VIctoria Hosptial
    Montreal, Quebec H3A1A1, Canada
  • Hoptial de Ranguell Service d'Urologie
    Toulouse, Cedex 31043, France
  • University Hospital Rotterdam, Department of Urology
    Rotterdam, Netherlands
  • Leighton Hospital Urology Research Dept., Michael Heal Outpatients Dept.
    Crewe, CW1 4QT, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2001 and a completion of Jun 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2005
First posted
Aug 8, 2005
Start
Jul 2001
CompletionActual
Jun 2007
Last update
Nov 29, 2007
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00127478
Lead sponsor
Abbott
First posted
Aug 8, 2005
Start date
Jul 2001
Completion
Jun 2007
Last update
Nov 29, 2007

Study contacts

Gary Gordon, MD
study director · Abbott
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atrasentan

Start the discussion